NEPH Relative Valuation
NEPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NEPH is overvalued; if below, it's undervalued.
Historical Valuation
Nephros Inc (NEPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -24.89. The fair price of Nephros Inc (NEPH) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.75
Fair
48.21
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Nephros Inc. (NEPH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -12.80. The thresholds are as follows: Strongly Undervalued below -54.05, Undervalued between -54.05 and -33.43, Fairly Valued between 7.83 and -33.43, Overvalued between 7.83 and 28.46, and Strongly Overvalued above 28.46. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
40.80
EV/EBIT
Nephros Inc. (NEPH) has a current EV/EBIT of 40.80. The 5-year average EV/EBIT is -4.84. The thresholds are as follows: Strongly Undervalued below -250.04, Undervalued between -250.04 and -127.44, Fairly Valued between 117.75 and -127.44, Overvalued between 117.75 and 240.35, and Strongly Overvalued above 240.35. The current Forward EV/EBIT of 40.80 falls within the Historic Trend Line -Fairly Valued range.
2.88
PS
Nephros Inc. (NEPH) has a current PS of 2.88. The 5-year average PS is 2.80. The thresholds are as follows: Strongly Undervalued below -1.76, Undervalued between -1.76 and 0.52, Fairly Valued between 5.09 and 0.52, Overvalued between 5.09 and 7.37, and Strongly Overvalued above 7.37. The current Forward PS of 2.88 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Nephros Inc. (NEPH) has a current P/OCF of 0.00. The 5-year average P/OCF is -9.37. The thresholds are as follows: Strongly Undervalued below -221.12, Undervalued between -221.12 and -115.24, Fairly Valued between 96.51 and -115.24, Overvalued between 96.51 and 202.38, and Strongly Overvalued above 202.38. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Nephros Inc. (NEPH) has a current P/FCF of 0.00. The 5-year average P/FCF is 12.85. The thresholds are as follows: Strongly Undervalued below -312.35, Undervalued between -312.35 and -149.75, Fairly Valued between 175.45 and -149.75, Overvalued between 175.45 and 338.05, and Strongly Overvalued above 338.05. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Nephros Inc (NEPH) has a current Price-to-Book (P/B) ratio of 5.73. Compared to its 3-year average P/B ratio of 2.79 , the current P/B ratio is approximately 105.66% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about 59.32% higher. Nephros Inc (NEPH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.45% , the current FCF yield is about -100.00% lower.
6.14
P/B
Median3y
2.79
Median5y
3.60
4.74
FCF Yield
Median3y
-4.38
Median5y
-7.45
Competitors Valuation Multiple
The average P/S ratio for NEPH's competitors is 0.00, providing a benchmark for relative valuation. Nephros Inc Corp (NEPH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 35.42%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NEPH increased by 293.54% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 12.93 to 41.66.
The secondary factor is the Margin Expansion, contributed 35.96%to the performance.
Overall, the performance of NEPH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Nephros Inc (NEPH) currently overvalued or undervalued?
What is Nephros Inc (NEPH) fair value?
How does NEPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Nephros Inc (NEPH) as of Dec 05 2025?
What is the current FCF Yield for Nephros Inc (NEPH) as of Dec 05 2025?
What is the current Forward P/E ratio for Nephros Inc (NEPH) as of Dec 05 2025?